MGF — a peptide studied for muscle, tendon, ligament, and bone tissue repair after mechanical stress.
Also known as: Mechano Growth Factor
MGF, short for Mechano Growth Factor, is a splice variant of IGF-1 that's produced specifically when tissue is mechanically loaded or damaged. When muscles contract hard, when ligaments stretch under force, or when bone is stressed, the body locally generates this short-lived signaling peptide to recruit repair cells and kick off regeneration.
What makes MGF interesting to researchers is that it's the body's own response to physical stress — a built-in repair signal rather than an external mimic. Most studies focus on a synthetic fragment called the MGF E peptide (and variants like MGF-C25E and T-MGF-19E), which captures the unique C-terminal sequence that distinguishes MGF from standard IGF-1 and appears to drive the regenerative effects.
The peptide has been studied across tendons, ligaments, bone, and periodontal tissue, with consistent findings around enhanced cell proliferation, better survival under stress, and accelerated tissue rebuilding. Its action is rapid and local, suggesting it works as a launch signal that activates longer-running repair programs in the surrounding tissue.
1 vendor carries MGF.
Compare prices →Tendon healing is slow and often incomplete because tenocytes — the cells that build and maintain tendon tissue — need to migrate into the injury site, proliferate, and lay down new extracellular matrix. A 2015 study using a synthetic MGF E peptide (MGF-C25E) in tenocyte cultures found that the peptide significantly enhanced tenocyte invasion through a transwell barrier, a standard test of how well repair cells can navigate into damaged tissue (1).
The mechanism traced back to two connected pathways. MGF-C25E increased phosphorylation of focal adhesion kinase (FAK) and ERK1/2 — signaling proteins that tell cells to move and divide — and ramped up the activity of matrix metalloproteinase-2 (MMP-2), an enzyme that clears a path through tissue for migrating cells. Blocking any one of these (FAK, ERK1/2, or MMP-2) shut down the invasion effect, confirming the chain of action. The authors noted this was the first evidence that MGF-C25E specifically enhances tenocyte invasion, positioning the peptide as a candidate for tendon repair research.
Ligament injuries — particularly anterior cruciate ligament (ACL) tears — present a brutal healing challenge because the injured tissue ends up in a low-oxygen environment that kills off the very cells needed for repair. A 2019 study examined MGF E peptide in this exact scenario, using both ACL fibroblast cultures under hypoxic conditions and a rabbit ACL rupture model (2).
Under severe low-oxygen stress, ACL fibroblasts normally enter apoptosis — programmed cell death — driven by HIF-1α and the caspase cascade. MGF E peptide blocked this process by acting through mitochondrial protection pathways alongside MEK-ERK1/2 and PI3K-Akt signaling, two of the main survival circuits cells use to resist stress. Treated cells survived where untreated ones died.
In the live ACL rupture model, the peptide reduced HIF-1α levels, cut apoptosis, and pushed cells back into proliferation mode. It also accelerated angiogenesis — the formation of new blood vessels feeding the repair zone — by recruiting pro-angiogenic cells through the SDF-1α/CXCR4 axis and upregulating VEGF, the master signal for new vessel growth. Restoring blood supply early appears to be a key part of how MGF supports ligament regeneration.
Bone defects and fractures depend on osteoblasts — bone-building cells — to proliferate, differentiate, and mineralize new tissue at the injury site. A 2020 study systematically classified 52 different MGF E peptide variants into four categories and tested them on MC3T3-E1 osteoblast cultures and a rabbit bone defect model (3).
One variant, T-MGF-19E, stood out across every measure. It strongly promoted osteoblast proliferation by accelerating the cell cycle, significantly enhanced osteoblast differentiation as measured by alkaline phosphatase activity and differentiation-related gene expression, and produced the most pronounced mineralization — the deposition of calcium and phosphate that turns soft tissue into bone. In the rabbit bone defect model, even low-dose T-MGF-19E significantly accelerated healing of the injury. The findings suggest that not all MGF fragments are equivalent, and that specific peptide lengths and species-derived sequences may have meaningfully different potency for bone repair applications.
The periodontal ligament — the connective tissue holding teeth in their sockets — is constantly under mechanical load from biting and chewing, and it remodels in response to that force. A 2024 study identified MGF as the molecular link between occlusal force and periodontal regeneration (4).
When the periodontal ligament was loaded under normal biting forces, it produced MGF locally, and that MGF strongly enhanced ligament remodeling. In cultured periodontal ligament stem cells, MGF amplified their differentiation into fibroblasts — the cells that build new ligament tissue — and the effect compounded with mechanical stimulation rather than simply replacing it. The signaling ran through Fyn and FAK kinases and downstream MAPK/ERK1/2 and p38 phosphorylation, the same general circuitry MGF uses in tendon and ligament tissue.
The authors framed this as a mechanochemical coupling effect: MGF and physical force work together, each amplifying the other. They proposed MGF-based adjuvant treatment as a potential strategy for patients with weakened bite force or damaged periodontium, where natural mechanical signaling alone isn't enough to drive regeneration.
Reported side effects in the published MGF research are minimal — across the cell culture work and the rabbit injury models in the available citations, no significant adverse effects were noted (1, 2, 3, 4). Long-term safety in humans hasn't been formally characterized because the necessary trials haven't been completed, and most work to date has used synthetic E peptide fragments rather than full MGF, which may differ in real-world behavior.
The body of MGF evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.
Because MGF is a splice variant of IGF-1 and shares regenerative signaling pathways with growth factors that fall under anti-doping rules, athletes in tested sports should review current WADA status before considering use.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.